Compare AstraZeneca plc (AZN) vs Ford Motor Company (F) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Ford (F) trades at $13.87, down 0.9% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with profitability metrics negative. Recent developments include a labor deal with Unifor, J.D. Power quality recognition, and plans for a $30,000 EV truck in 2027. Analyst consensus is mixed with 35% buy ratings and a $15.00 price target.

Ford faces execution risks in EV transition amid competitive pressures, though valuation appears reasonable with P/E of 11.84 and P/S of 0.29. The stock offers value potential if management can stabilize profitability, but investors should monitor EV execution and margin recovery given current negative ROE of -14.87% and ongoing operational challenges.